Buy AromaTaseHemmer Online
Tamoxifen has been supplanted by aromatase inhibitors as the first option for postmenopausal women with steroid receptor-positive illness. Anastrozole, letrozole, and exemestane are superior to tamoxifen in terms of therapeutic response, progression-free survival, and overall survival, according to a number of prospective randomized trials. Several medicinal compounds have been studied in recent, extensive clinical trials when used as adjuvants. Anastrozole significantly lowers than tamoxifen the incidence of both local and distant recurrences in women with steroid receptor-positive illness, according to the ATAC trial. The consecutive use of tamoxifen, letrozole, and exemestane was investigated in two further sizable clinical trials. Letrozole showed to be superior in terms of recurrences after a median follow-up of 2.4 years. Also, taking exemestane following tamoxifen significantly lowers the risk of relapses and contralateral breast malignancies.